Condition
SSc-Systemic Sclerosis
Total Trials
5
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Early P 1 (3)
P 1 (1)
Trial Status
Recruiting4
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07674147Early Phase 1Not Yet Recruiting
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
NCT07193810Early Phase 1Recruiting
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
NCT07491523RecruitingPrimary
Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
NCT07355972Early Phase 1RecruitingPrimary
Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC
NCT07315087Phase 1Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Showing all 5 trials